Rimonabant Meta-Analysis Reveals Increased Risk Of Psychiatric Events – The Lancet

Study introduces nothing new about the obesity drug that has not been discussed with regulatory authorities, Sanofi-Aventis responds to “The Pink Sheet” DAILY.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet